NSCLC Stage II

11 registered clinical trials studyying NSCLC Stage II — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell L NCT07493980	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2
Recruiting	Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectab NCT07410975	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2
Recruiting	A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial L NCT07323732	Memorial Sloan Kettering Cancer Center	Phase 2
Recruiting	PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study NCT06945484	University of Utah	N/A
Not Yet Recruiting	Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: A Multi - Omics Pe NCT06856798	Ziming Li	—
Recruiting	Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSC NCT04865250	University Hospital Heidelberg	Phase 2
Completed	A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China NCT04830826	The First Affiliated Hospital of Guangzhou Medical University	—
Recruiting	Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients NCT04205552	University Hospital, Essen	Phase 2
Active Not Recruiting	Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small NCT03999710	Memorial Sloan Kettering Cancer Center	Phase 2
Unknown	The Role of Microbiota on the Development of Lung Cancer NCT03454685	Xiaorong Dong	—
Unknown	Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations NCT01470716	National Cancer Center, Korea	Phase 2